Early Findings Show Activity for Cytokine Agonist in BCG-Unresponsive Bladder Cancer

Tony Berberabe, MPH
Published: Thursday, Jun 27, 2019
Sam S. Chang, MD, MBA

Sam S. Chang, MD, MBA

Use of a cytokine agonist in combination with bacille Calmette-Guérin (BCG) was highly successful in stimulating an immune response in previously BCG-unresponsive patients with carcinoma in situ (CIS) high-grade nonmuscle invasive bladder cancer (NMIBC), according to early trial results presented by Sam S. Chang, MD, MBA, at the 2019 American Urological Association (AUA) Annual Meeting.

“This agent appears to be well tolerated when combined with BCG. It produced a significant CR rate in patients with CIS, as well as a significant disease-free rate for Ta/T1 disease, but this is clearly early on for the study, so longer follow-up is mandatory to determine the ultimate success of this therapy,” Chang concluded.

References

  1. Chamie K, Lee J, Rock A, Rhode P, Soon-Shiong P, Chang SS. A multicenter clinical trial of intravesical bacillus Calmette-Guerin (BCG) in combination with N-803 in patients with BCG-unresponsive high grade nonmuscle invasive bladder cancer. Presented at: 2019 American Urological Association Annual Meeting; May 3-6, 2019; Chicago, IL. Abstract LBA-18.
  2. Steinberg RL, Thomas LJ, O’Donnell MA. Bacillus Calmette-Guérin (BCG) treatment failures in non-muscle invasive bladder cancer: what truly constitutes unresponsive disease. Bladder Cancer. 2015;1(2):105-116. doi: 10.3233/BLC-150015.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x